Mission
The McGill mRNA Therapeutics Platform advances mRNA research by providing high-quality, affordable bioproduction services, analytical expertise, technology development, and training. We support researchers and industry partners in transforming innovative ideas into therapeutic solutions through collaboration, scientific excellence, and accessible infrastructure.
Vision
To be a world-leading hub for mRNA therapeutics that accelerates scientific discovery, enables translational research, fosters strategic partnerships, and trains the next generation of innovators in RNA medicine.
Scientific Leadership
Our team of experts at the McGill mRNA Therapeutics Platform is dedicated to advancing the next generation of mRNA-based therapeutics through rigorous research and biomanufacturing excellence.
Dr. Thomas Duchaine
Scientific Director: Thomas provides strategic and scientific leadership for the platform. He guides the research direction, ensuring alignment with translational and commercial objectives. His extensive experience in RNA biology and therapeutic development is instrumental in driving the platform's success.
Dr. Panagiotis Prinos (Takis)
Network Director: Takis leads coordination of the RNA innovation network across McGill University, Université de Sherbrooke, and IRCM. He focuses on fostering collaborative research and creating a unified scientific community within the mRNA therapeutics space.
Dr. Balaji Ramachandran
Platform Manager: Oversees the platform’s day-to-day operations, project management, and client coordination. Balaji ensures that all bioproduction and analytical projects are executed with scientific excellence and technical precision.
Rania Leventis
Chief Research Technician: Supports the production and quality assessment of mRNA for various research projects. Rania brings technical expertise to the biomanufacturing processes, ensuring the highest standards for all therapeutic mRNA produced on the platform.
Jothyswarupha Krishna Kumar
Research Assistant: Supports RNA research and development across multiple academic and industrial projects. Jothyswarupha assists in laboratory operations and data analysis to accelerate the translation of innovative ideas into therapeutic solutions.
Rajan Leung
Researcher: Doctoral student researching mRNA stability and developing novel stabilizers for RNA therapeutics. Rajan’s research contributes to enhancing the efficacy and shelf-life of mRNA-based treatments through innovative chemical and biological strategies.
Aby Sall
Intern: Aby Sall is a master’s student in Bioengineering and Biomedical Engineering at McGill University. As an intern with the mRNA Manufacturing Platform, she works on the process development and optimization of mRNA production workflows on the Quantoom Ntensify™ Mini platform. Her work focuses on evaluating alternative reagents, improving process efficiency, and reducing manufacturing costs to support more accessible and scalable mRNA production.